Methicillin-resistant Staphylococcus aureus (MRSA) is a clinically important gram-positive pathogen found in both the hospital and outpatient settings. The newly marketed oritavancin (The Medicine Company’s Orbactiv), dalbavancin (Allergan’s Dalvance/Xydalba), and tedizolid (Bayer HealthCare/Merck’s Sivextro) have greatly increased treatment options for MRSA infections, making the hospital-treated MRSA market highly competitive. Within this crowded space, new agents will need to demonstrate improvements over current therapies and justify their premium pricing in light of significant competition, including that coming from generics. This report provides a comprehensive overview and analysis of the epidemiology, patient populations, and current and emerging medical practice and therapies for MRSA infections in the major pharmaceutical markets. The insights presented in this report are derived from primary and secondary research, company presentations and sales data, and detailed interviews with recognized key opinion leaders (KOLs). This report includes a 2016-2026, epidemiology-based, annualized, bottom-up forecast of current and emerging MRSA therapies in the major pharmaceutical markets.
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
Primary research: 31 country-specific interviews with infectious disease specialists.
Epidemiology: Diagnosed events of the MRSA population by country and indication, including hospital- and community-acquired MRSA.
Population segments in market forecast: Complicated skin and skin structure infections (cSSSIs) and surgical site infections (SSIs), bloodstream infections (BSIs), complicated intra-abdominal infections (cIAIs), urinary tract infections (UTIs), and nosocomial pneumonia (NP).
Emerging therapies: Phase III: 7 drugs; Phase II: 7 drugs.